Meanwhile, the BSE Sensex was down 127.22 points, or 0.52%, to 24,554.81.

Huge volumes were traded on the counter. On BSE, so far 40.46 lakh shares were traded in the counter, compared with an average volume of 6.3 lakh shares in the past one quarter. The stock was locked at a low of Rs 75.80 so far during the day. The stock hit a high of Rs 96.20 in intraday trade. The stock hit a 52-week low of Rs 51.50 on 26 March 2015. The stock hit a record high of Rs 115 on 10 August 2015. The stock had outperformed the market over the past one month till 12 January 2016, declining 0.58% compared with 1.45% decline in the Sensex. The scrip had, however, underperformed the market in past one quarter, shedding 10.11% as against Sensex's 8.26% decline.

The mid-cap company has an equity capital of Rs 40.93 crore. Face value per share is Re 1.

Marksans Pharma's Goa plant reportedly got a notice of deficiency from UK Medicines and Healthcare products Regulatory Agency (MHRA). The drug regulator has found violations in goods manufacturing practices (GMP) norms in the Goa plant. The UK drug market contributes 40% to the company's revenue, report added.

Marksans Pharma's consolidated net profit rose 11.9% to Rs 34.87 crore on 21.4% rise in net sales to Rs 255.53 crore in Q2 September 2015 over Q2 September 2014.

Mumbai-based Marksans Pharma is engaged in research, manufacturing and marketing of generic pharmaceutical formulation in the global market.